SCM
PTGX icon

Sterling Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Sterling Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5K Sell
216
-161
-43% -$16.8K ﹤0.01% 1766
2026
Q1 		$39.7K Sell
377
-1
-0.3% -$89 ﹤0.01% 1742
2025
Q4 		$33K Buy
378
+237
+168% +$19.4K ﹤0.01% 1972
2025
Q3 		$9.37K Sell
141
-2
-1% -$114 ﹤0.01% 2517
2025
Q2 		$7.9K Buy
143
+80
+127% +$3.84K ﹤0.01% 2273
2025
Q1 		$3.05K Buy
63
+3
+5% +$126 ﹤0.01% 2402
2024
Q4 		$2.32K Hold
60
– – ﹤0.01% 2749
2024
Q3 		$2.7K Buy
+60
New +$2.42K ﹤0.01% 2042

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sterling Capital Management's PTGX Position: Q2 2026 in Review

Sterling Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 43% in Q2 2026, selling an estimated $16.8K and leaving 216 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1766.

Sterling Capital Management first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $39.7K in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Sterling Capital Management held 216 shares of Protagonist Therapeutics worth $26.5K as of Q2 2026.
  • Sterling Capital Management sold 161 Protagonist Therapeutics shares in Q2 2026, an estimated $16.8K.
  • Protagonist Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1766 holding.
  • Sterling Capital Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Protagonist Therapeutics position peaked at $39.7K in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.